Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier
A one-shot gene-editing cholesterol therapy could soon be a reality
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
The licensed intellectual property covers methods and designs for CAR constructs engineered to function in myeloid cell populations
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
